We are live on ! Find out more
BBH icon

VanEck Biotech ETF

111 hedge funds and large institutions have $180M invested in VanEck Biotech ETF in 2023 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 23 increasing their positions, 36 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

85% more call options, than puts

Call options by funds: $375K | Put options by funds: $203K

10% more capital invested

Capital invested by funds: $164M → $180M (+$16.5M)

4.79% more ownership

Funds ownership: 32.83%37.62% (+4.8%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

3% less funds holding

Funds holding: 115111 (-4)

36% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 36

36% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 11

Holders
111
Holders Change
-4
Holders Change %
-3.48%
% of All Funds
1.74%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
7
Increased
23
Reduced
36
Closed
11
Calls
$375K
Puts
$203K
Net Calls
+$172K
Net Calls Change
-$120K

BBH Hedge Fund Activity: Q2 2023 in Review

111 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q2 2023, worth a combined $180M — up 10% from $164M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of BBH and 7 opened new positions — a net loss of 4 holders — while 36 trimmed existing stakes and 23 added.

The largest buyer was Miller Investment Management, adding an estimated $11M. The largest seller was Susquehanna International Group, cutting an estimated $1.78M.

  • 111 institutional investors held VanEck Biotech ETF (BBH) as of Q2 2023, down from 115 in Q1 2023.
  • Funds reported $180M of VanEck Biotech ETF stock for Q2 2023, up 10% quarter-over-quarter.
  • 7 funds opened new VanEck Biotech ETF positions in Q2 2023 and 11 closed out, a net change of -4 holders.
  • The largest VanEck Biotech ETF buyer in Q2 2023 was Miller Investment Management, an estimated $11M added.
  • The largest VanEck Biotech ETF seller in Q2 2023 was Susquehanna International Group, an estimated $1.78M sold.

Based on aggregated 13F filings for Q2 2023.